Effects of PARP Inhibitor Therapy on p53-Deficient Hematopoietic Stem and Progenitor Cell Fitness

内科学 医学 肿瘤科 造血干细胞移植 癌症 癌症研究 免疫学 移植
作者
Jeremy T. Baeten,Irenaeus C.C. Chan,Daniel C. Link,Kelly L. Bolton
出处
期刊:Blood [Elsevier BV]
卷期号:138 (Supplement 1): 3275-3275 被引量:2
标识
DOI:10.1182/blood-2021-151373
摘要

Abstract Poly (ADP-ribose) polymerase (PARP) inhibitors are an important new class of anti-cancer therapies. Therapy-related myeloid neoplasia (tMN) has been reported following PARPi therapy and is associated with adverse outcomes. We have previously shown, in retrospective data, that prior chemotherapy increases the incidence of clonal hematopoiesis (CH), especially in DNA damage response (DDR) pathway genes including TP53, PPM1D, and CHEK2 and is associated with progression to tMN. In particular, patients who receive PARPi therapy are more likely to have CH compared to other therapies or untreated patients. In the IMPACT study of CH in 10,156 cancer patients, exposure to PARPi were more likely to have CH (33%) compared to untreated patients (16%). This was particularly pronounced for DDR gene mutations, with 25% of PARPi treated patients with DDR CH compared to 2% of untreated patients. In multivariate analysis accounting for demographics and exposure to other chemotherapy or radiation therapy, exposure to PARPi conferred an increased risk of DDR CH (OR = 3.6, 95% CI 1.5-8.5, p = 0.004). From these data, we hypothesize that mutations in DDR pathway genes provide a fitness advantage to hematopoietic stem/progenitor cells (HSPCs) following PARPi treatment, leading to clonal hematopoiesis. A major limitation, however of our previous work in retrospective clinical samples, is the inability to completely adjust for the confounding effect of prior exposure to cytotoxic therapy (in particular platinum therapies) and germline BRCA1/2 mutations; both which have been shown or hypothesized to increase the risk of tMN. To test whether PARPi exposure might provide a fitness advantage to HSPCs independent of prior exposure to other therapies, we first examined the response of CRISPR-gene edited TP53-/- MOLM13 cells to the PARPi Olaparib and, as a control, Cisplatin. As expected, TP53-/- cells had increased resistance to both agents, though the response was much more pronounced in Cisplatin-treated cells (Figure 1A,B). Next, we implemented a mouse model of TP53-mutant clonal hematopoiesis, by generating mixed bone marrow chimeras transplanted with a 1:9 ratio of wildtype (CD45.1) to TP53 R172H+/- (CD45.2) cells. The "baseline" contribution of TP53 R172H+/- (CD45.2) cells to peripheral blood leukocytes 8 weeks after transplantation was determined by flow cytometry. Mice were then randomized into the following three cohorts: 1) Cisplatin (6mg/kg on days 1, 8, and 15); 2) Olaparib (50mg/kg daily for 3 weeks); and 3) vehicle alone. Peripheral blood chimerism was assessed 3, 9, and 12 weeks after initiating treatment. In addition, the contribution of TP53 R172H+/- to lineage -Sca1 +Kit + (LSK) cells in the bone marrow was determined. Cisplatin treatment resulted in a significant increase in the contribution of TP53 R172H+ to peripheral blood total leukocytes, granulocytes, and bone marrow LSK cells (Figure 1C-E). In contrast, Olaparib treated mice showed no change in CD45 chimerism. From these results we conclude that p53-deficiency does not confer a strong fitness advantage to mouse HSPCs in response to PARPi treatment. This suggests that the strong association observed between prior PARPi therapy, CH and tMN in clinical cohorts may in part be due to the confounding effects of prior (often heavy) exposure to platinum-based therapy. However, the majority of patients receiving PARPi have germline heterozygous BRCA1/2 mutations that could be contributing to their hematopoietic response to PARPi therapy. Experiments are underway to test this possibility by analyzing mixed bone marrow chimeras carrying heterozygous mutations of both Brca1 and Trp53. Figure 1 Figure 1. Disclosures No relevant conflicts of interest to declare.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
闵不悔完成签到,获得积分10
6秒前
阳光火车完成签到 ,获得积分10
7秒前
cc完成签到,获得积分10
10秒前
合适的寄灵完成签到 ,获得积分10
11秒前
量子星尘发布了新的文献求助10
12秒前
科研通AI5应助cc采纳,获得10
13秒前
铜泰妍完成签到 ,获得积分10
14秒前
贝贝完成签到 ,获得积分10
19秒前
Lrcx完成签到 ,获得积分10
20秒前
Wen完成签到 ,获得积分10
21秒前
盘尼西林完成签到 ,获得积分10
23秒前
LOVE0077完成签到,获得积分10
26秒前
zhao完成签到,获得积分10
28秒前
BINBIN完成签到 ,获得积分10
38秒前
ambrose37完成签到 ,获得积分10
40秒前
量子星尘发布了新的文献求助10
46秒前
fufufu123完成签到 ,获得积分10
50秒前
开心的大娘完成签到,获得积分10
50秒前
www完成签到 ,获得积分10
52秒前
末末完成签到 ,获得积分10
1分钟前
无为完成签到 ,获得积分10
1分钟前
白嫖论文完成签到 ,获得积分10
1分钟前
上官若男应助忧伤的步美采纳,获得10
1分钟前
科研通AI2S应助科研通管家采纳,获得10
1分钟前
1分钟前
从心随缘完成签到 ,获得积分10
1分钟前
花花发布了新的文献求助10
1分钟前
牛奶面包完成签到 ,获得积分10
1分钟前
1分钟前
岁月如歌完成签到 ,获得积分0
1分钟前
1分钟前
Li完成签到,获得积分10
1分钟前
张琨完成签到 ,获得积分10
1分钟前
1分钟前
sunnyqqz完成签到,获得积分10
1分钟前
热情的乘风完成签到,获得积分20
1分钟前
1分钟前
霍凡白完成签到,获得积分10
1分钟前
1分钟前
Feng发布了新的文献求助20
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022